Pituitary apoplexy after leuprolide

Davis, Anu Bhalla; Goel, Shefali; Picolos, Michalis; Wang, Min; Lavis, Victor R.

doi:10.1007/s11102-006-8616-6

Cited by 29 publications

(16 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Possible mechanisms are the long-standing stimulatory effect on tumoral gonadotropin secretion (Table 1) and an increase in cellular volume, precipitating the compression of sellar structures. As in the presented case, this clinical syndrome occurs even in the absence of an actual hemorrhage or infarction [20].…”

Section: Discussionsupporting

confidence: 77%

Sellar collision tumor involving pituitary gonadotroph adenoma and chondroma: a potential clinical diagnosis

et al. 2009

View full text Add to dashboard Cite

We report on a 74-year-old male patient who presented with progressive neuroophthalmologic symptoms soon after the administration of a long-acting gonadotropin-releasing hormone agonist for treatment of a prostate cancer. Imaging revealed a destructively growing and extensively calcified sellar mass inconsistent with a pituitary adenoma. A transseptal transsphenoidal tumor mass reduction yielded a histological diagnosis of a collision tumor comprised of a gonadotroph adenoma intermingled with osteochondroma. We discuss a potential causal relationship between the administration of the long-acting gonadotropin-releasing hormone agonist and the sudden appearance of the previously unsuspected sellar lesion. Although the association of these two tumors is very likely coincidental, the possibility of causal relationship is addressed.

show abstract

Section: Discussionsupporting

confidence: 77%

Sellar collision tumor involving pituitary gonadotroph adenoma and chondroma: a potential clinical diagnosis

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Macchia et al reported that long-acting leuprolide injection neither reduced serum estradiol and FSH levels nor prevented a rapid relapse of OHSS [13]. Furthermore, the first dose of leuprolide can induce pituitary apoplexy in a patient with asymptomatic gonadotroph adenoma [40].…”

Section: Treatmentmentioning

confidence: 99%

Ovarian Hyperstimulation Caused by Gonadotroph Pituitary Adenoma – Review

Halupczok¹,

Kluba-Szyszka²,

Bidzińska−Speichert³

et al. 2015

Adv Clin Exp Med

View full text Add to dashboard Cite

Ovarian hyperstimulation syndrome (OHSS) occurs mostly as an iatrogenic complication of assisted reproductive technology. Gonadotroph pituitary adenomas are rarely associated with OHSS. To the authors' knowledge, to date only 30 cases of spontaneous ovarian stimulation associated with gonadotroph adenomas have been reported in women and only 2 in children. The most common symptoms in such cases included menstrual disturbances, abdominal or pelvic pain, abdominal distension and increased girth. Galactorrhea, nausea and vomiting were also reported. Neurological symptoms occurred when the size of the pituitary tumor reached at least 20 mm. Transvaginal ultrasound examination usually demonstrated enlarged multicystic ovaries. MRIs of the pituitary revealed macroadenomas up to 61 mm in maximum diameter. The hormonal profiles of the reported cases showed normal or elevated FSH levels, suppressed LH levels, elevated estradiol levels and supranormal concentrations of prolactin. Transsphenoidal surgery is the therapy of choice, however other treatment modalities can be utilized in selected cases (Adv Clin Exp Med 2015, 24, 4, 695-703).

show abstract

“…Fifteen patients, including the current one, have been reported to have suffered pituitary apoplexy after GnRH agonist administration (Table 1) [1][2][3][4][5][6][7][8][9][10][11][12][13][14]. All reported patients had a gonadotropin secreting macroadenoma.…”

Section: Discussionmentioning

confidence: 99%